

Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues

Downloaded from: https://research.chalmers.se, 2024-10-28 08:53 UTC

Citation for the original published paper (version of record): Pfeiffer, P., Nilsson, J., Gallud, A. et al (2024). Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues. Nucleic Acids Research, 52(17): 10102-10118. http://dx.doi.org/10.1093/nar/gkae722

N.B. When citing this work, cite the original published paper.

research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology. It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004. research.chalmers.se is administrated and maintained by Chalmers Library

Supplementary Data:

Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues

Pauline Pfeiffer¹, Audrey Gallud^{2,3}, Jesper R. Nilsson^{1,4}, Tom Baladi^{1,5}, Hoang-Ngoan Le^{1,5}, Mattias Bood^{5,6}, Malin Lemurell⁷, Anders Dahlén⁵, Morten Grøtli⁶, Elin K. Esbjörner^{2*}, L. Marcus Wilhelmsson^{1*}

¹Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemivägen 10, SE-41296 Gothenburg, Sweden

²Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, SE-41296 Gothenburg, Sweden.

³Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, SE-43181 Gothenburg, Sweden.

⁴LanteRNA (Stealth Labels Biotech AB), c/o Chalmers Ventures AB, Vera Sandbergs allé 8, SE-41296 Gothenburg, Sweden

⁵Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden ⁶Department of Chemistry and Molecular Biology, University of Gothenburg P.O. Box 462, SE-40530 Gothenburg, Sweden

⁷Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

* To whom correspondence should be addressed.

Contents

1. pA ribonucleoside triphosphate synthesis	1
1.1 Synthetic scheme	1
1.2 Experimental procedures	2
1.3 Spectral data	7
1.4 UV-vis and fluorescence spectroscopy	20
2. Analysis of nucleoli under ActD exposure	21
3. Pulse-Chase Experimental Setup	22
4. Accumulation of pATP and 2CNqATP in SH-SY5Y cells before and after exchar FBA treatment solutions to fresh cell culture medium (CCM)	nging the23
5. Cytotoxicity assessment of 2CNqAMP	24
6. Intensity profile analysis of 2CNqAMP subcellular distribution in Huh-7 cells	25
7. Comparison of flow cytometry readout with lysate readout using plate reader	26
8. Flow cytometry histograms showing FBA uptake as function of time	27
9. Fitting of the uptake kinetics	
10. Uptake of 2CNqATP and 2CNqAMP in the presence of competitors	29
11. Uptake of pATP in the presence of ATP as competitor	30
12. Titration of RNA to 2CNqAMP	31
13. Agarose gel of total RNA extracts of cells exposed to 2CNqAMP	32
14. Images of cells exposed to 2CNqAMP and hydroxyurea	33
15. Standard curve for determination of 2CNqA concentration in extracted RNA	34
16. Emission spectra of RNA extracts from cells exposed to pATP or tC ^O TP	35
References	

1. pA ribonucleoside triphosphate synthesis

1.1 Synthetic scheme



1.2 Experimental procedures

All reactions were performed in flame-dried or oven-dried glassware under a nitrogen atmosphere unless otherwise noted. Reagents were purchased from various chemical vendors and either used as received or purified according to standard techniques. The following reagents used for the triphosphorylation were bought from Sigma-Aldrich: DCA deblock for ÄKTA, CAP A for ÄKTA, CAP B1 and B2 for ÄKTA, BTT Activator. All solvents used for reactions were HPLC-grade and purchased dry. Microwave reactions were performed with a Biotage Initiator using single mode microwave irradiation with temperature and pressure control and with fixed hold time on. Reactions were monitored by TLC on silica gel plates analyzed under UV (254 nm), and by UPLC-MS (ESI/UV), using a Waters Acquity system equipped with either an Acquity UPLC HSS C18 column (1.8 µm, length 50 mm, ID 2.1 mm) running a gradient of water-MeCN (95:5) to water-MeCN (5:95), with the water eluent containing 1% formic acid (pH 3) or an Acquity UPLC BEH C18 column (1.7µm, length 50 mm, ID 2.1 mm) running a gradient of water-MeCN (95:5) to water-MeCN (5:95), with the water eluent containing 1% ammonium hydroxide (pH 10). Flash chromatography was performed by automated column chromatography using pre-packed silica columns. HPLC purification was performed with ammonia as modifier on a preparative HPLC system with an Xbridge C18 column (10 μ m, 250 \times 50 mm). ¹H and ¹³C NMR spectra were recorded on a Bruker 500 MHz system equipped with a CryoProbe. ³¹P NMR spectra were recorded at 300 K on a Bruker 500 MHz system. All shifts are recorded in ppm relative to the deuterated solvent: CDCl₃ (7.26 ppm for ¹H and 77.16 ppm for ¹³C), DMSO-d₆ (2.50 ppm for ¹H and 39.52 ppm for ${}^{13}C$) or D₂O.

(2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-

7-yl)tetrahydrofuran-3,4-diyl dibenzoate (3): 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1, 20 g, 71.6 mmol) was dissolved in MeCN (480 mL). trimethylsilyl (E)-N-(trimethylsilyl)acetimidate (19.5 mL, 78.7 mmol) was added dropwise. The mixture was stirred at RT for 20 min. (2S,3R,4R,5R)-2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate (2, 46.9 g, 93.0 mmol) was added in one portion, followed by dropwise addition of trimethylsilyl trifluoromethanesulfonate (15.2 mL, 78.7 mmol). The reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was allowed to cool to RT and diluted with EtOAc (200 mL). The organic phase was washed with aq. satd. NaHCO₃ (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄, filtered, concentrated *in vacuo*, absorbed onto Celite and purified by flash column chromatography (Hept:EtOAc 90:10 to 70:30, KP-Sil 330 g) to yield **3** (31.0 g, 60%) as a white solid.

¹H NMR (500 MHz, CDCl₃) δ 8.58 (s, 1H), 8.09 – 8.13 (m, 2H), 7.99 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.92 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.49 – 7.64 (m, 6H), 7.39 (dt, *J* = 22.8, 7.8, 7.8 Hz, 4H), 6.67 (d, *J* = 5.4 Hz, 1H), 6.09 – 6.17 (m, 2H), 4.90 (dd, *J* = 12.3, 3.1 Hz, 1H), 4.80 (q, *J* = 3.5, 3.5, 3.4 Hz, 1H), 4.68 (dd, *J* = 12.3, 3.6 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃) δ 166.2, 165.5, 165.2, 153.3, 151.4, 151.1, 133.94, 133.91, 133.7, 132.1, 129.98, 129.96, 129.8, 129.4, 128.9, 128.8, 128.71, 128.66, 128.5, 117.9, 86.9, 80.8, 74.3, 71.6, 63.6, 53.8.

HRMS (ESI-TOF) m/z calcd for $C_{32}H_{23}CIIN_3O_7$ [M + H]+ : 724.0347, found: 724.0384.

(2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-(4-chloro-5-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate (4): Compound 3 (31 g, 42.8 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.99 g, 0.86 mmol) were dissolved in THF (360 mL) to which triethylamine (59 mL, 428 mmol) was added. The reaction mixture was cooled to -78°C and stirred for 5 min before 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (9.3 mL, 64.2 mmol) was added dropwise to the mixture. The reaction mixture was then allowed to warm to RT and successively heated to 80 °C for 36 h. The reaction mixture was allowed to cool to RT, concentrated *in vacuo*, absorbed onto Celite and purified by flash-chromatography (KP-Sil, 330 g, Hept:EtOAc, 95:5 to 70:30 to yield the target compound (4, 23.5 g, 76 %) as a white solid.

¹H NMR (500 MHz, DMSO) δ 8.58 (s, 1H), 8.33 (s, 1H), 7.98 (ddd, J = 11.8, 8.3, 1.2 Hz, 4H), 7.83 (dd, J = 8.3, 1.2 Hz, 2H), 7.59 – 7.69 (m, 3H), 7.50 (dt, J = 9.8, 8.1, 8.1 Hz, 4H), 7.39 – 7.43 (m, 2H), 6.76 (d, J = 5.4 Hz, 1H), 6.35 – 6.39 (m, 1H), 6.14 – 6.18 (m, 1H), 4.79 – 4.89 (m, 2H), 4.69 (dd, J = 12.1, 5.0 Hz, 1H), 1.28 (s, 12H).

¹³C NMR (126 MHz, DMSO) δ 165.4, 164.7, 164.4, 152.8, 152.5, 150.9, 138.7, 133.94, 133.87, 133.5, 129.4, 129.3, 129.23, 129.17, 128.75, 128.72, 128.71, 128.6, 128.2, 119.8, 86.7, 83.6, 79.3, 73.3, 70.8, 63.5, 54.9, 24.5.

HRMS (ESI-TOF) m/z calcd for C₃₈H₃₅BClN₃O₉ [M + H]+ : 724.2233, found: 724.2245.

tert-Butyl (3-Iodonaphthalen-2-yl)carbamate (5): A oven-dried 3-necked 1L round-bottom flask equipped with a magnetic stir bar was charged with 3-iodo-2-naphthoic acid (5a, 24.8 g, 83.2 mmol) dissolved in toluene (320 mL) and triethylamine (14 mL, 100.0 mmol) was added. The flask was fitted with a reflux condenser and an addition funnel. The reaction was heated to reflux and diphenyl phosphorazidate (21.6 mL, 100.0 mmol) in toluene (80 mL) was added dropwise to the reaction mixture over a total period of 60 min. The rate of addition was kept to 1 drop every 2-5 s and bubbles was observed after 5 min of addition. The addition funnel was rinsed with additional toluene (20 mL). After 15 min of stirring at reflux the bubble formation stopped. After an additional 15 min the addition funnel was charged with 2-methylpropan-2-ol (40 mL, 416.0 mmol) in toluene (60 mL), which was cautiously (note: the formed intermediate is extremely reactive and must be handled with care) added dropwise to the reaction mixture at reflux. The reaction was stirred at reflux for an additional 3 h. The reaction mixture was allowed to cool to RT, transferred to a separatory funnel and the material was washed sequentially with water (3x500 mL), aq. satd. NaHCO₃ (3x250 mL) followed by brine (1x500 mL). The resulting orange solution was dried over MgSO₄, filtered and concentrated in vacuo to yield 5 (20.0 g, 65 %) as a beige solid.

¹H NMR (500 MHz, DMSO) δ 8.63 (s, 1H), 8.52 (s, 1H), 7.94 (s, 1H), 7.86 (dd, *J* = 14.9, 8.1 Hz, 2H), 7.46 – 7.54 (m, 2H), 1.48 (s, 9H).

¹³C NMR (126 MHz, DMSO) δ 153.4, 138.1, 136.1, 132.7, 132.2, 127.3, 126.8, 126.4, 126.1, 123.5, 96.7, 79.2, 28.1.

HRMS (ESI-TOF) m/z calcd for $C_{15}H_{16}INO_2$ [M + H]+ : 370.0304, found: 370.0295.

(2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-(5-(3-((tert-

butoxycarbonyl)amino)naphthalen-2-yl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-

yl)tetrahydrofuran-3,4-diyl dibenzoate (6): Compound 4 (22 g, 30.4 mmol), tert-butyl (3iodonaphthalen-2-yl)carbamate (5, 10.7 g, 29.0 mmol), bis(triphenylphosphine)palladium(II) dichloride (1.02 g, 1.45 mmol), potassium carbonate (10.0 g, 72.4 mmol) was dissolved in DME (300 ml) and the reaction was stirred at 80 °C for 24 h. The reaction mixture was concentrated *in vacuo*, absorbed on Celite and purified by flash-chromatography (KP-Sil 330 g, Hept:EtOAc 90:10 to 40:60) to yield 6 (18.2 g, 75 %) as a yellow solid.

¹H NMR (500 MHz, DMSO) δ 8.64 (s, 1H), 8.40 (s, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 7.99 (d, J = 7.3 Hz, 2H), 7.88 – 7.94 (m, 5H), 7.84 (d, J = 6.6 Hz, 2H), 7.63 – 7.68 (m, 2H), 7.57 (t, J = 7.54 Hz, 2H)

7.3, 7.3 Hz, 1H), 7.4 – 7.53 (m, 8H), 6.87 (d, J = 4.7 Hz, 1H), 6.39 (t, J = 5.1, 5.1 Hz, 1H), 6.23 (t, J = 5.9, 5.9 Hz, 1H), 4.91 (q, J = 5.1, 5.0, 5.0 Hz, 1H), 4.82 (dd, J = 12.1, 3.5 Hz, 1H), 4.71 (dd, J = 12.1, 5.0 Hz, 1H), 1.27 (s, 9H).

¹³C NMR (125 MHz, DMSO) δ 165.4, 164.6, 164.5, 153.2, 151.5, 151.3, 150.5, 135.6, 134.0, 133.9, 133.5, 133.1, 130.6, 129.5, 129.4, 129.3, 129.2, 129.17, 128.9, 128.8, 128.7, 128.6, 128.5, 128.3, 127.4, 127.0, 126.5, 125.5, 125.1, 116.6, 112.9, 86.6, 78.8, 73.8, 31.2, 27.9, 22.1, 13.9.

HRMS (ESI-TOF) m/z calcd for C₄₇H₃₉ClN₄O₉ [M + H]+ : 839.2484, found: 839.2485.

(2R,3R,4S,5R)-2-(2,3,5,6-Tetraazacyclopenta[de]tetracen-2(6H)-yl)-5-

(hydroxymethyl)tetrahydrofuran-3,4-diol (8): Compound 6 (7 g, 8.3 mmol) was dissolved in DMF (18 mL) to which 1,4-diazabicyclo[2.2.2]octane (7.5 mL, 16.7 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (2.5 mL, 16.7 mmol) was added. The reaction mixture was stirred at 75 °C for 17 h. The reaction mixture was allowed to cool to RT and was subsequently co-evaporated with toluene (5x15 mL). The crude product was purified by flash chromatography (KP-Sil 100 g, DCM:MeOH 100:0 to 95:5) which yielded a mixture of products consisting of Boc- and de-Boc protected product (7a and 7b, 3.1 g). The material obtained was used in the next step without further purification.

The mixture of compound **7a** and **7b** (2.85 g) was dissolved in MeCN (32 mL) and sodium methanolate (3.9 mL, 21.3 mmol) was added. The reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated *in vacuo*, absorbed onto Celite and purified by flash chromatography (KP-Sil 25 g, DCM:MeOH 100:0 to 90:10) to yield **8** (0.55 g, 17 % over two steps) as a white solid.

¹H NMR (500 MHz, DMSO) δ 10.90 (s, 1H), 8.19 (s, 1H), 8.15 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.70 (s, 1H), 7.55 (s, 1H), 7.33 – 7.43 (m, 2H), 5.95 (d, J = 6.4 Hz, 1H), 5.40 (d, J = 6.5 Hz, 1H), 5.18 (d, J = 4.5 Hz, 1H), 4.55 (q, J = 6.3, 6.3, 6.3 Hz, 1H), 4.15 (q, J = 4.6, 4.6, 4.6 Hz, 1H), 3.97 (q, J = 3.8, 3.8, 3.8 Hz, 1H), 3.68 (d, J = 12.0 Hz, 1H), 3.55 – 3.61 (m, 1H), 2.54 (s, 1H).

¹³C NMR (126 MHz, DMSO) δ 155.2, 153.6, 147.2, 137.4, 132.6, 129.6, 129.2, 128.5, 127.2, 126.6, 126.3, 124.7, 122.4, 120.3, 113.4, 113.3, 110.4, 106.7, 88.5, 85.6, 74.1, 70.9, 61.9

HRMS (ESI-TOF) m/z calcd for $C_{21}H_{18}N_4O_4$ [M + H]+ : 391.1406, found: 391.1405.

(2R,3R,4S,5R)-2-(2,3,5,6-tetraazacyclopenta[de]tetracen-2(6H)-yl)-5-((bis(4-

methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3,4-diol (9): Compound 8 (150 mg, 0.38 mmol) was co-evaporated with pyridine (25 mL) thrice before pyridine (3 mL) was added, and the flask was placed in an ice bath (0 °C) to which DMTr-Cl (143 mg, 0.42 mmol) was added in one portion. The reaction mixture was stirred for 5 min before being returned to RT and stirred for 18 h. MeOH (3 mL) was added and the reaction mixture was extracted with EtOAc (50 mL), washed with water (20 mL) and brine (10 mL). The organic layers were dried over MgSO₄, concentrated *in vacuo*, absorbed onto Celite and purified by flash chromatography (KP-Sil 25 g, flushed with 2% Et₃N in DCM prior to use, EtOAc in DCM: 0 to 50%) to yield 9 (60 mg, 23 %) as a light brown solid.

¹H NMR (500 MHz, DMSO- d_6) δ 10.90 (bs, 1H), 8.19 (s, 1H), 7.74 (s, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 9.9 Hz, 2H), 7.52 (s, 1H), 7.40 (d, J = 7.5 Hz, 3H), 7.33 – 7.39 (m, 2H), 7.28 (t, J = 8.3 Hz, 6H), 7.20 (t, J = 7.3 Hz, 1H), 6.84 (dd, J = 8.9, 6.9 Hz, 4H), 6.03 (d, J = 4.5 Hz, 1H), 5.57 (bs, 1H), 4.67 (t, J = 4.8 Hz, 1H), 4.39 (t, J = 5.0 Hz, 1H), 4.07 (q, J = 4.4 Hz, 1H), 3.66 (s, 3H), 3.65 (s, 3H), 3.22 (m, 2H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 158.1, 158.0, 155.5, 153.6, 147.6, 144.8, 137.6, 135.7, 135.6, 132.7, 129.8, 129.7, 129.5, 127.9, 127.8, 127.1, 126.7, 126.6, 126.4, 124.7, 122.2, 120.3, 113.3, 113.2, 112.8, 110.7, 106.5, 88.4, 85.6, 82.8, 74.2, 70.6, 63.7, 55.0, 54.9.

HRMS (ESI-TOF) m/z calcd for C₄₂H₃₆N₄O₆ [M+H]+: 693.2713, found: 693.2729.

((2R,3S,4R,5R)-5-(2,3,5,6-tetraazacyclopenta[de]tetracen-2(6H)-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl hydrogen triphosphate (10): Reaction was performed following procedure described by Baladi *et al.*¹ using CPG-bound pA nucleoside (9, 400 mg, 18 umol/g loading, 0.0072 mmol). Briefly, steps were performed as following:

- a. 5'-DMT removal: the support was washed with a flow of DCA deblock until the filtrate was colorless, whereafter it was washed with ACN (5 x 5 mL).
- b. Coupling: *N*,*N*-diisopropyl-4*H*-benzo[*d*][1,3,2]dioxaphosphinin-2-amine (345 mg, 1.36 mmol) was dissolved in 5 mL ACN and reacted portion wise with the support (3 equally charged couplings with reaction times 60 s, 60 s, and 90 s, respectively). To each coupling, BTT activator (2.4 mL) was also added. The support was subsequently washed with ACN (3 x 5 mL).
- c. Oxidation: Pyridine/Water/Iodine (9/1/12.7 v/v/w, 5 mL) for 45 s, followed by ACN wash (3 x 5 mL) and drying of the support in an argon flow.
- d. Triphosphorylation: Two injections of bis(tetrabutylammonium) dihydrogen diphosphate (0.5 M, 5 ml) were carried out and allowed to react for 15 min and 18 hours, respectively. The support was subsequently rinsed with DMF (5 mL), water (3 x 5 mL), ACN (5 mL) and then dried in an argon flow.
- e. Cleavage and Purification: Cleavage of the triphosphate was done with AMA (50/50 v/v mix of 23% aq. NH4OH and 40% aq. methylamine, 5 mL) for 2 h at RT. After 2 h, the AMA filtrate was purged in a round-bottom flask and the support was rinsed 3 times with 23% aq. NH4OH solution. After freeze-drying the mixture, purification by HPLC (XBridge BEH C18 OBD, 5 μ m 10x250 mm column, 25 mL/min, A: dibutylammonium acetate 50 mM pH7 in 95% water and 5% ACN, B: ACN, 15%–45% B over 10 min followed by 100% B over 2 min) was performed to yield pATP (2.7 mg, 60 %, as determined by UV absorption) as a white solid (dibutylammonium salt). The salt form could subsequently be exchanged to ammonium using standard phase HPLC in ammonium carbonate or ammonium ion-exchange columns.

¹H NMR (500 MHz, D₂O, 25°C) δ 4.37 (s, 2H), 4.44 (s, 1H), 4.67 (d, *J* = 4.2 Hz, 2H), 5.88 (d, *J* = 5.9 Hz, 1H), 6.89 (s, 1H), 7.24 (z, 3H), 7.34–7.42 (m, 2H), 7.55 (s, 1H), 7.70 (s, 1H).

¹³C NMR (126 MHz, D₂O) δ 134.3, 131.9, 129.5, 127.2, 126.7, 126.5, 125.3, 122.7, 118.2, 114.3, 112.3, 105.0, 86.8, 83.4, 74.7, 70.7, 65.6.

³¹P NMR (202 MHz, D₂O, 25°C) δ -22.58 (*J* = 20.1), -11.08 (*J* = 19.9), -8.72.

HRMS (ESI-TOF) m/z calcd for C₂₁H₂₁N₄O₁₃P₃ [M+H]+: 631.0396, found: 631.0416.

((2R,3S,4R,5R)-5-(8-cyano-2,3,5,6-tetraazaaceanthrylen-2(6H)-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate (12): 2CNqAMP was synthesized using a similar method than pATP 10, starting from the corresponding 2CNqA

nucleoside, but replacing step d with a simple water wash to hydrolyze the cyclic phosphoramidite intermediate. Compound **12** was isolated as a yellow solid (2 mg, 40 %).

¹H NMR (500 MHz, D₂O) 4.04 - 4.2 (m, 2H), 4.36 (s, 1H), 4.53 (t, J = 4.2 Hz, 1H), 4.72 (t, J = 5.7 Hz, 1H), 5.99 (d, J = 6.0 Hz, 1H), 6.76 (s, 1H), 6.87 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.38 (s, 1H), 7.81 (s, 1H).

³¹P NMR (202 MHz, D₂O) 1.75. MS (ESI+, MeOH) m/z: 446.1 [M+H]+.

((2R,3S,4R,5R)-5-(8-cyano-2,3,5,6-tetraazaaceanthrylen-2(6H)-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl hydrogen triphosphate (13): 2CNqATP was synthesized as previously described by our group.⁵ An additional ¹³C NMR experiment was recorded to strengthen characterization data.

¹H NMR (500 MHz, D₂O) δ 7.88 (s, 1H), 7.47 (s, 1H), 7.34 (d, J = 7.9 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.83 (s, 1H), 6.04 (d, J = 5.8 Hz, 1H), 4.76 (s, 1H), 4.61 (s, 1H), 4.39 (s, 1H), 4.31 (s, 2H).

³¹P NMR (202 MHz, D₂O) δ -22.48 (bs, 1P), -11.19 (d, J=19.9 Hz, 1P), -9.25 (bs, 1P).

¹³C NMR (126 MHz, D₂O) δ 154.3, 152.2, 146.1, 137.6, 126.9, 125.1, 123.7, 120.9, 119.1, 111.7, 111.2, 109.1, 107.7, 86.7, 83.6, 83.5, 74.6, 70.6.

1.3 Spectral data

(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate *(3)*



(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate (4)



tert-butyl (3-iodonaphthalen-2-yl)carbamate (5)



(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(5-(3-((tertbutoxycarbonyl)amino)naphthalen-2-yl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7yl)tetrahydrofuran-3,4-diyl dibenzoate *(6)*





(2R,3R,4S,5R)-2-(2,3,5,6-tetraazacyclopenta[de]tetracen-2(6H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol *(8)*



(2R,3R,4S,5R)-2-(2,3,5,6-tetraazacyclopenta[de]tetracen-2(6H)-yl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3,4-diol (9)

((2R,3S,4R,5R)-5-(2,3,5,6-tetraazacyclopenta[de]tetracen-2(6H)-yl)-3,4dihydroxytetrahydrofuran-2-yl)methyl hydrogen triphosphate (10)





((2R,3S,4R,5R)-5-(8-cyano-2,3,5,6-tetraazaaceanthrylen-2(6H)-yl)-3,4dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate (*12*)



Downloaded from https://academic.oup.com/nar/article/52/17/10102/7736808 by guest on 03 October 2024



((2R,3S,4R,5R)-5-(8-cyano-2,3,5,6-tetraazaaceanthrylen-2(6H)-yl)-3,4dihydroxytetrahydrofuran-2-yl)methyl hydrogen triphosphate (*13*)



150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 f1 (ppm)





1.4 UV-vis and fluorescence spectroscopy

Supplementary Table S1. Photophysical characteristics of the FBA-TPs used in this study, recorded at room temperature (*ca.* 22 °C). For buffer conditions, see materials and methods section or the indicated references. ε_{260} : molar absorptivity at 260 nm; Φ_F : fluorescence quantum yield referenced to quinine sulphate in 0.5 M H₂SO₄; $\lambda_{abs,max}$: wavelength of absorption maximum; $\lambda_{em,max}$: wavelength of emission maximum; $\varepsilon_{max, FBA} \propto \Phi_F$: brightness at the absorption maximum; $\varepsilon_{max, FBA} \propto \Phi_F$: brightness at 405 nm which is the excitation wavelength used for the microscopy and flow cytometry experiments in this study; τ : fluorescence lifetime

FBA-TP	ε_{260} (M ⁻¹ cm ⁻¹)	Ф _F (%)	λ _{abs, max} (nm)	λ _{em, max} (nm)	$\varepsilon_{\max, FBA} \times \Phi_F$ $(M^{-1} \text{ cm}^{-1})$	$\varepsilon_{405, FBA} \ge \Phi_F$ (M ⁻¹ cm ⁻¹)	τ (ns)
tC ^o TP	11000 ²	27	360	453	2700	417	3.4
2CNqATP	14600 ³	485	352 ⁵	471 ⁵	4900	504	9.9 ⁵
рАТР	22300 ⁴	49	386	420	6000	909	6.0

2. Analysis of nucleoli under ActD exposure

Supplementary Table S2. Analysis of nucleoli area under ActD exposure using 2CNqATP uptake as readout. Three images per condition (ActD treated or 2CNqATP only, *i.e.* control) were used for analysis. Using the fluorescent channel and the transmission image nuclei were identified and nucleoli inside them were used for analysis. Using the polygon selection tool in ImageJ nucleoli were outlined and measured. Visualization of this data is presented in the main Figure 2D.

Actinomy	cinD treated	Control		
#nucleolus	Area [µm ²]	#nucleolus	Area [µm ²]	
1	5.858	1	27.624	
2	1.967	2	15.560	
3	1.381	3	11.553	
4	3.640	4	13.983	
5	1.506	5	6.053	
6	5.670	6	8.611	
7	3.965	7	8.910	
8	5.542	8	6.480	
9	4.604	9	6.096	
10	2.558	10	7.929	
11	1.108	11	32.678	
12	1.918	12	17.532	
13	6.569	13	9.331	
14	4.142	14	7.615	
15	3.724	15	16.862	
16	4.059	16	9.080	
17	2.720	17	2.803	
18	2.092	18	11.883	
19	8.034	19	16.779	
20	4.059	20	6.109	
21	1.841	21	5.942	
22	3.389	22	5.983	
23	1.967	23	4.644	
24	5.607	24	4.477	
25	4.937	25	24.268	
26	2.008	26	9.373	
27	4.937	27	5.732	
28	1.716	28	4.142	
29	1.046	29	9.875	
30	2.720	30	13.975	
Mean	3.509	Mean	11.063	
Standard	1.781	Standard	7.029	
Deviation		Deviation		

3. Pulse-Chase Experimental Setup

Supplementary Table S3. Tested conditions using ActD and NaAsO₂. Cells were first exposed to 2.5 μ M 2CNqATP over three hours for maximum fluorescent signal. Hereafter, cells were washed once with PBS and exposed to indicated concentrations of ActD or NaAsO₂. Effects were observed under confocal laser scanning microscope over time. Conditions used for data presented in the main text are highlighted in bold.

Treatment	Concentration	Observation	
ActD	1 μM	No visible effect after several hours.	
	2 µM	After 3 h nucleoli visibly smaller.	
	4 μM	After 1.5 h nucleoli become visibly smaller,	
		cells start dying at around 3 h .	
NaAsO ₂	0.5 μM	No visible effect after several hours.	
	50 μM	Cells start dying at around 2 h, nucleoli remain	
		intact.	
	200 µM	Cells die within one hour	



Figure S1. A Left: Huh-7 cells exposed to 2.5 μ M 2CNqATP for comparison. Right: Huh-7 cells were first exposed to 4 μ M ActD for 1.5 h. Then 2CNqATP was added while ActD was kept in the medium. Indicated times in the figure are total exposure times at imaging time. **B** Huh-7 cells exposed to 2CNqATP and NaAsO₂. Left: cells were first exposed to 50 μ M NaAsO₂ for one hour and then 2.5 μ M 2CNqATP was added. Right: Cells were first incubated with 2.5 μ M 2CNqATP for three hours, then washed once with PBS and hereafter exposed to 50 μ M NaAsO₂ for 1.5 h. Note that brightness and contrast of the images are adjusted for better visibility of nucleolar structure. Due to different 2CNqATP exposure times the signal intensity varied. Scale bars 20 μ m.

4. Accumulation of pATP and 2CNqATP in SH-SY5Y cells before and after exchanging the FBA treatment solutions to fresh cell culture medium (CCM)



Supplementary Figure S2. Confocal microscopy images of SH-SY5Y cells before (24 h after exposure) and after the exchange of the 2.5 μ M FBA treatment solution with normal CCM, showing the clearance as function of time. Scale bars represent 20 μ m.

5. Cytotoxicity assessment of 2CNqAMP



Supplementary Figure S3. Cytotoxicity of 2CNqAMP to Huh-7 cells determined using the AlamarBlue assay. Relative metabolic activity was referenced to that of untreated cells. All treatments were performed in triplicates in a single experiment. The data is presented as mean \pm standard deviation.

6. Intensity profile analysis of 2CNqAMP subcellular distribution in Huh-7 cells



Supplementary Figure S4. Representative fluorescence intensity line profile of cellular 2CNqAMP intensity after 24 h of incubation of Huh-7 cells at 37 °C with 2.5 μ M 2CNqAMP in the cell medium. The nucleoli display a 2.3 \pm 0.1 times higher emission intensity compared to the nuclei and cytosol.

7. Comparison of flow cytometry readout with lysate readout using plate reader



Supplementary Figure S5. Comparison between readout methods of the cellular uptake of 2CNqATP (yellow) and 2CNqAMP (red) at 37 °C at various concentration after 24 h. Filled circles with solid lines represent readout of flow cytometry readout of detached Huh-7 WT cells after exposure. Empty circles with dotted lines show readout of lysed cells using a plate reader. Lines were added to guide the eyes. Experiment was performed once including two exposures of each compound at each concentration (mean \pm S.D.).

8. Flow cytometry histograms showing FBA uptake as function of time



Supplementary Figure S6. Representative flow cytometry histograms showing the distribution of cellular fluorescence intensity as function of incubation time for Huh-7 cells. The blue histograms show the background signal of unexposed Huh-7 cells. Left panel: Cells exposed to 2CNqAMP (2.5μ M) with lightest red directly after exposure ("0 min") and darkest red 250 min after exposure. Right panel: Cells exposed to 2CNqATP (2.5μ M) with lightest green directly after exposure ("0 min") and darkest green directly after exposure. Time interval was 5 min over 15 min, followed by an interval of 15 min to 60 min exposure time and finally 60 min interval until a total exposure time of 250 min was reached.

9. Fitting of the uptake kinetics



Supplementary Figure S7. Uptake kinetics of 2CNqAMP (left) and 2CNqATP (right) in Huh-7 cells at 37 °C measured using flow cytometry. Cells were exposed to 2.5 μ M 2CNqAMP or 2CNqATP, respectively. Data is presented as mean fluorescence intensity (MFI) ± S.D. (n=3). Each experiment was done three times, indicated in triangles (dashed line), squares (solid line), and dots (dotted line). Lines represent the fitted mono-exponential curve as detailed in Supplementary Table S4.

Supplementary Table S4. Fitting details of the uptake kinetics presented in Supplementary Figure S7. Using OriginPro (Version 9.7.0.188) a mono-exponential fit (ExpDec1; $y = A1^{exp}(-x/t1) + y0$) in global data fit mode was performed using Levenberg Marquard iteration algorithm (iterations until fit converged, chi-square tolerance value 1E-9 was reached). The fit included all three replicates with instrumental weighting (square of the reciprocal of the error values) and a shared time constant *i.e.* shared for the triplicates during fitting procedure. The table shows the resulting fit values with the time constants highlighted in bold.

Results for fit of monophosphate (2CNqAMP) uptake				Results for fit of triphosphate (2CNqATP) uptake		
	Replicate 1	Replicate 2	Replicate 3	Replicate 1	Replicate 2	Replicate 3
y0	$316497.39633 \\ \pm 18934.51137$	$222725.81616 \\ \pm 15126.43651$	$120373.67685 \\ \pm 7275.02599$	$205342.48712 \\ \pm 8935.19101$	$281824.20989 \\ \pm 10736.64207$	$99992.65641 \\ \pm 7489.47324$
A1	-312155.39145 ± 18964.11055	-217355.75712 ± 15182.48138	-116344.62157 ± 8083.96919	-192318.37472 ± 11354.53877	-277360.3993 ± 11386.24771	$\begin{array}{r} -100985.11065 \\ \pm 10118.66503 \end{array}$
t1	34.89731 ± 3.0207	34.89731 ± 3.0207	34.89731 ± 3.0207	74.21937 ± 7.27118	74.21937 ± 7.27118	74.21937 ± 7.27118

10. Uptake of 2CNqATP and 2CNqAMP in the presence of competitors



Supplementary Figure S8. Representative flow cytometry histograms of the uptake of 2CNqATP and 2CNqAMP into Huh-7 cells at 37 °C in presence of respectively ATP and AMP as competitors, corresponding to the mean cell intensity data shown in Figure 3f in the main text. The grey histograms show the background signal of the unexposed cells. Left: Cells exposed to 2.5 μ M 2CNqAMP (red) for 3 h, with and without 625 μ M AMP. Right: Cells exposed to 2.5 μ M 2CNqATP (green) for 3 h, with and without 625 μ M ATP.

11. Uptake of pATP in the presence of ATP as competitor



Supplementary Figure S9. Uptake of pATP in Huh-7 cells at 37 °C determined using flow cytometry. Cells were exposed to 2.5 μ M pATP for 3 h, with and without 625 μ M ATP. Data is presented as mean \pm S.D. (n=2).

12. Titration of RNA to 2CNqAMP



Supplementary Figure S10. Fluorescence excitation spectra of 2CNqAMP (10 μ M) in the presence of increasing concentrations of unlabelled RNA. The excitation maxima are indicated by the vertical line at 352 nm.

13. Agarose gel of total RNA extracts of cells exposed to 2CNqAMP



Supplementary Figure S11. 2% agarose gel (%w/v) of total RNA extracts of Huh-7 cells exposed 2.5 μ M 2CNqAMP over indicated time. For control 2CNqAMP was added to cell lysate before extraction. 500 ng RNA of each sample was loaded and SYBRsafe was added to the gels for detection. Indicated bands are 28S rRNA (I), 18 S rRNA (II), xylene cyanol dye present in the loading dye (grey III) small RNAs (IV), and bromophenol blue present in the loading dye (grey V). Ladder is RiboRuler High Range (Thermo Scientific). Gel was run for 1 h at 100 V.



14. Images of cells exposed to 2CNqAMP and hydroxyurea

Supplementary Figure S12. A Representative emission spectra of RNA extracts from Huh-7 cells that had been exposed to 2.5 μ M 2CNqAMP and 15 nM hydroxyurea for 24 h (dashed dark red line). For control, RNA extraction was done as shown in Figure 4a. **B** Microscopy images of Huh-7 cells exposed to 2.5 μ M 2CNqATP and various concentrations of hydroxyurea (HU) after 4 h. Scale Bars 20 μ m.

15. Standard curve for determination of 2CNqA concentration in extracted RNA

		Concentration	Integrated Area	Corrected for QY	Corrected for Excitation	
		[nM]	[A.U.]	Factor 3.9	Factor 1.1	
		0	3,24E-06	8,30E-07	7,55E-07	
		0,91	4,61E+06	1,18E+06	1,07E+06	
		1	3,54E+06	9,06E+05	8,24E+05	
		1,82	6,92E+06	1,77E+06	1,61E+06	
		2,5	7,47E+06	1,92E+06	1,74E+06	
		3	9,36E+06	2,40E+06	2,18E+06	
		5	1,58E+07	4,05E+06	3,69E+06	
		9,1	2,96E+07	7,58E+06	6,89E+06	
6x10 ⁶ 5x10 ⁶ 5x10 ⁶	6x10 ⁶ - 5x10 ⁶ - 4x10 ⁶ -				Fitting Results Equation	y = a + b * x
σ	-		/		Plot	excit correction
fe	0106			,	Weight	No Weighting
Ľa	3x10° -				Intercept	$106477,46624 \pm 95356,4509$
- O	-				Slope	735477,33824 ± 23820,46376
lpt	2×10^{6} –	/			Residual Sum of Squares	2,05E+11
]	Pearson's r	0,99687
	1	_]	R-Square (COD)	0,99375
	1x10 ⁶ –	•			Adj. R-Square	0,9927
		2	4 Concentrat	6 ion [nm]	8 10	

Supplementary Figure S13. Recorded values of a dilution series of 2CNqATP in milliQ and correction for change in quantum yield and excitation at emission wavelength (top table) and the resulting standard curve. Linear fit was applied with fitting results presented in table in the graph.

16. Emission spectra of RNA extracts from cells exposed to pATP or $tC^{O}TP$



Supplementary Figure S14. Representative emission spectra of RNA extracts from Huh-7 cells that had been exposed to 2.5 μ M pATP (left, blue) or tC^OTP (right, orange) for 24 h. Controls, performed as indicated for 2CNqA in main Figure 4a, are shown in faint corresponding color. Water was recorded to confirm appearance of the Raman peak at the same wavelength as in the sample (grey dotted line).

References

- Baladi, T. *et al.* Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery. *J. Am. Chem. Soc.* 143, 5413–5424 (2021).
- Sandin, P. *et al.* Characterization and use of an unprecedentedly bright and structurally non-perturbing fluorescent DNA base analogue. *Nucleic Acids Research* 36, 157–167 (2008).
- Wypijewska del Nogal, A. *et al.* Getting DNA and RNA out of the dark with 2CNqA: a bright adenine analogue and interbase FRET donor. *Nucleic Acids Research* 48, 7640-7652 (2020).
- Bood, M. *et al.* Pentacyclic adenine: a versatile and exceptionally bright fluorescent DNA base analogue. *Chemical Science* 9, 3494–3502 (2018).
- Nilsson, J.R. *et al.* Multiphoton characterization and live cell imaging using fluorescent adenine analogue 2CNqA. *Physical Chemistry Chemical Physics* 25, 20218-20224 (2023).